CO2020003977A2 - Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéutico - Google Patents
Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéuticoInfo
- Publication number
- CO2020003977A2 CO2020003977A2 CONC2020/0003977A CO2020003977A CO2020003977A2 CO 2020003977 A2 CO2020003977 A2 CO 2020003977A2 CO 2020003977 A CO2020003977 A CO 2020003977A CO 2020003977 A2 CO2020003977 A2 CO 2020003977A2
- Authority
- CO
- Colombia
- Prior art keywords
- nitrogen
- pharmaceutical use
- containing heteroaryl
- heteroaryl compound
- compound
- Prior art date
Links
- -1 Nitrogen-containing heteroaryl compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091006303 SLC2A9 Proteins 0.000 abstract 1
- 102100022720 Solute carrier family 2, facilitated glucose transporter member 6 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017194005 | 2017-10-04 | ||
| PCT/JP2018/037007 WO2019069973A1 (ja) | 2017-10-04 | 2018-10-03 | 含窒素ヘテロアリール化合物およびその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020003977A2 true CO2020003977A2 (es) | 2020-04-24 |
Family
ID=65994698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0003977A CO2020003977A2 (es) | 2017-10-04 | 2020-03-31 | Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéutico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10752596B2 (enExample) |
| EP (1) | EP3693358B1 (enExample) |
| JP (1) | JP7125882B2 (enExample) |
| KR (1) | KR20200064101A (enExample) |
| CN (1) | CN111148735B (enExample) |
| AR (1) | AR113270A1 (enExample) |
| AU (1) | AU2018345221A1 (enExample) |
| BR (1) | BR112020004857A2 (enExample) |
| CA (1) | CA3074989A1 (enExample) |
| CL (1) | CL2020000898A1 (enExample) |
| CO (1) | CO2020003977A2 (enExample) |
| IL (1) | IL273573A (enExample) |
| MX (1) | MX2020003816A (enExample) |
| PE (1) | PE20200846A1 (enExample) |
| PH (1) | PH12020550403A1 (enExample) |
| RU (1) | RU2020115045A (enExample) |
| SG (1) | SG11202003005PA (enExample) |
| TW (1) | TW201922706A (enExample) |
| WO (1) | WO2019069973A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156698B (zh) * | 2019-06-06 | 2020-10-13 | 沈阳海诺威医药科技有限公司 | 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途 |
| CN113181206B (zh) * | 2021-04-30 | 2023-07-14 | 青岛大学 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
| CA3244306A1 (en) * | 2022-01-07 | 2023-07-13 | Horizon Therapeutics Ireland Dac | GLUT9 HETEROCYCLIC INHIBITORS FOR THE TREATMENT OF A DISEASE |
| CN114805192B (zh) * | 2022-03-30 | 2023-05-23 | 华南理工大学 | 一种含2-羟基苯甲酸的三环类xor/urat1双重抑制剂及其制备方法与应用 |
| WO2024167952A1 (en) * | 2023-02-08 | 2024-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oxidatively cleavable organophosphate drugs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ292843B6 (cs) * | 1996-07-18 | 2003-12-17 | Merck Frosst Canada & Co. | Derivát pyridinu a farmaceutický prostředek s jeho obsahem |
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| EP1070714B1 (en) * | 1998-04-10 | 2004-08-04 | Japan Tobacco Inc. | Amidine compounds |
| JP2007501801A (ja) * | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ［１，２−ｂ］ピリダジン誘導体 |
| JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| JP2007176933A (ja) | 2005-11-29 | 2007-07-12 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP5162827B2 (ja) | 2005-12-27 | 2013-03-13 | ぺんてる株式会社 | 鉛筆芯の製造方法 |
| JP5330990B2 (ja) | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
| JP2009016193A (ja) * | 2007-07-05 | 2009-01-22 | Daihen Corp | 電気機器用樹脂ブッシング |
| HRP20140705T1 (hr) * | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| CN103037690B (zh) | 2010-03-24 | 2016-04-27 | 俄亥俄州立大学 | 用于葡萄糖转运抑制的组合物和方法 |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| CN105439946B (zh) | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| CN104306363B (zh) | 2014-10-31 | 2017-06-06 | 南京葆赫生物技术有限公司 | 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用 |
-
2018
- 2018-10-03 AU AU2018345221A patent/AU2018345221A1/en not_active Abandoned
- 2018-10-03 JP JP2018188038A patent/JP7125882B2/ja active Active
- 2018-10-03 AR ARP180102853A patent/AR113270A1/es unknown
- 2018-10-03 EP EP18864398.5A patent/EP3693358B1/en active Active
- 2018-10-03 MX MX2020003816A patent/MX2020003816A/es unknown
- 2018-10-03 SG SG11202003005PA patent/SG11202003005PA/en unknown
- 2018-10-03 KR KR1020207012149A patent/KR20200064101A/ko not_active Withdrawn
- 2018-10-03 US US16/150,989 patent/US10752596B2/en active Active
- 2018-10-03 CN CN201880064738.0A patent/CN111148735B/zh active Active
- 2018-10-03 PE PE2020000529A patent/PE20200846A1/es unknown
- 2018-10-03 WO PCT/JP2018/037007 patent/WO2019069973A1/ja not_active Ceased
- 2018-10-03 CA CA3074989A patent/CA3074989A1/en not_active Abandoned
- 2018-10-03 BR BR112020004857-7A patent/BR112020004857A2/pt not_active Application Discontinuation
- 2018-10-03 TW TW107134941A patent/TW201922706A/zh unknown
- 2018-10-03 RU RU2020115045A patent/RU2020115045A/ru unknown
-
2020
- 2020-03-24 IL IL273573A patent/IL273573A/en unknown
- 2020-03-31 CO CONC2020/0003977A patent/CO2020003977A2/es unknown
- 2020-04-02 CL CL2020000898A patent/CL2020000898A1/es unknown
- 2020-04-06 PH PH12020550403A patent/PH12020550403A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3693358A4 (en) | 2021-06-02 |
| EP3693358A1 (en) | 2020-08-12 |
| TW201922706A (zh) | 2019-06-16 |
| IL273573A (en) | 2020-05-31 |
| RU2020115045A (ru) | 2021-11-08 |
| EP3693358B1 (en) | 2023-02-22 |
| BR112020004857A2 (pt) | 2020-09-15 |
| CL2020000898A1 (es) | 2020-08-14 |
| WO2019069973A1 (ja) | 2019-04-11 |
| AU2018345221A1 (en) | 2020-05-07 |
| SG11202003005PA (en) | 2020-04-29 |
| PE20200846A1 (es) | 2020-08-18 |
| US10752596B2 (en) | 2020-08-25 |
| JP2019065009A (ja) | 2019-04-25 |
| US20190152926A1 (en) | 2019-05-23 |
| JP7125882B2 (ja) | 2022-08-25 |
| CN111148735A (zh) | 2020-05-12 |
| AR113270A1 (es) | 2020-03-11 |
| CA3074989A1 (en) | 2019-04-11 |
| MX2020003816A (es) | 2020-08-13 |
| CN111148735B (zh) | 2023-08-08 |
| PH12020550403A1 (en) | 2021-02-15 |
| KR20200064101A (ko) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020003977A2 (es) | Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéutico | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| BR112016024545A2 (pt) | derivados de pirazolo pirimidina e seu uso como inibidores de malt1 | |
| EA201892128A1 (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
| LT3577110T (lt) | 8-oksetan-3-il-3,8-diazabiciklo[3.2.1]oktan-3-ilo pakeistieji junginiai, kaip živ inhibitoriai | |
| MX2020012132A (es) | Compuestos de azapiridona y usos de los mismos. | |
| UA118259C2 (uk) | Гетероциклічні аміди як інгібітори кінази | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| IL291191A (en) | Cdk inhibitors and their use as pharmaceuticals | |
| MX378509B (es) | Compuesto de pirimidina y su uso farmaceutico. | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| BR112016009757A8 (pt) | “inibidores do vírus sincicial respiratório com base em quinazolina” | |
| CO2017005732A2 (es) | Compuestos de dihidropirimidin-2-ona y sus usos médicos | |
| TR201900680T4 (tr) | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. | |
| MX2016015856A (es) | Derivados de naftiridinadiona. | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| WO2017173302A3 (en) | Inhibitors of integrin alpha 5 beta 1 and methods of use | |
| IL282999A (en) | 1,3,4-oxadiazolone compound and pharmaceutical | |
| UY37681A (es) | Compuestos inhibidores de la actividad quinasa y su uso en aplicaciones terapéuticas | |
| IL285805A (en) | Quinazolinone compounds, compositions comprising same and uses thereof | |
| MX373441B (es) | Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt. | |
| CL2024003845A1 (es) | Compuesto de dihidrooxadiazinona y su uso farmacéutico. |